|
Macrogenics, Inc. (MGNX) Évaluation DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
MacroGenics, Inc. (MGNX) Bundle
Améliorez vos choix d'investissement avec la calculatrice DCF MacroGenics, Inc. (MGNX)! Passez en revue les données financières authentiques, ajustez les projections et les dépenses de croissance et observez instantanément comment ces changements affectent la valeur intrinsèque de MacroGenics, Inc. (MGNX).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.0 | 97.8 | 75.6 | 151.9 | 58.7 | 69.6 | 82.4 | 97.5 | 115.5 | 136.8 |
| Revenue Growth, % | 0 | 57.62 | -22.63 | 100.87 | -61.33 | 18.42 | 18.42 | 18.42 | 18.42 | 18.42 |
| EBITDA | -177.2 | -117.8 | -190.9 | -107.9 | 2.0 | -51.1 | -60.6 | -71.7 | -84.9 | -100.6 |
| EBITDA, % | -285.67 | -120.48 | -252.31 | -71.01 | 3.43 | -73.52 | -73.52 | -73.52 | -73.52 | -73.52 |
| Depreciation | 12.3 | 12.0 | 11.3 | 11.9 | 9.6 | 9.9 | 11.7 | 13.9 | 16.4 | 19.5 |
| Depreciation, % | 19.83 | 12.23 | 14.88 | 7.81 | 16.42 | 14.23 | 14.23 | 14.23 | 14.23 | 14.23 |
| EBIT | -189.5 | -129.7 | -202.1 | -119.8 | -7.6 | -54.5 | -64.6 | -76.4 | -90.5 | -107.2 |
| EBIT, % | -305.5 | -132.71 | -267.2 | -78.82 | -12.98 | -78.36 | -78.36 | -78.36 | -78.36 | -78.36 |
| Total Cash | 215.8 | 272.5 | 243.6 | 154.3 | 229.8 | 69.6 | 82.4 | 97.5 | 115.5 | 136.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 12.7 | 23.1 | 10.4 | 56.2 | 10.4 | 15.7 | 18.5 | 22.0 | 26.0 | 30.8 |
| Account Receivables, % | 20.55 | 23.61 | 13.73 | 37 | 17.65 | 22.51 | 22.51 | 22.51 | 22.51 | 22.51 |
| Inventories | .0 | .0 | 4.4 | 1.5 | 1.2 | 1.2 | 1.5 | 1.7 | 2.0 | 2.4 |
| Inventories, % | 0.000001612279 | 0.000001022871 | 5.8 | 0.95498 | 2.08 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 |
| Accounts Payable | 4.3 | 8.0 | 15.5 | 4.9 | 6.4 | 6.9 | 8.2 | 9.7 | 11.5 | 13.6 |
| Accounts Payable, % | 6.95 | 8.21 | 20.49 | 3.22 | 10.97 | 9.97 | 9.97 | 9.97 | 9.97 | 9.97 |
| Capital Expenditure | -4.3 | -5.9 | -6.2 | -3.6 | -1.8 | -3.7 | -4.4 | -5.2 | -6.1 | -7.3 |
| Capital Expenditure, % | -6.92 | -6.04 | -8.2 | -2.38 | -3 | -5.31 | -5.31 | -5.31 | -5.31 | -5.31 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -189.5 | -117.8 | -190.9 | -120.0 | -7.6 | -52.9 | -62.6 | -74.2 | -87.8 | -104.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -189.9 | -118.3 | -170.0 | -165.3 | 47.9 | -51.5 | -57.1 | -67.6 | -80.1 | -94.9 |
| WACC, % | 11.81 | 11.74 | 11.77 | 11.81 | 11.81 | 11.79 | 11.79 | 11.79 | 11.79 | 11.79 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -245.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -97 | |||||||||
| Terminal Value | -989 | |||||||||
| Present Terminal Value | -566 | |||||||||
| Enterprise Value | -812 | |||||||||
| Net Debt | -67 | |||||||||
| Equity Value | -745 | |||||||||
| Diluted Shares Outstanding, MM | 62 | |||||||||
| Equity Value Per Share | -12.03 |
What You Will Gain
- Comprehensive Financial Model: MacroGenics, Inc.'s (MGNX) actual data facilitates accurate DCF valuation.
- Complete Forecast Flexibility: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates provide immediate feedback as you make adjustments.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
- Adaptable and Reusable: Designed for versatility, enabling ongoing use for in-depth forecasts.
Key Features
- Customizable Financial Inputs: Adjust essential metrics such as revenue projections, R&D expenses, and operating costs.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and other financial metrics.
- High-Precision Accuracy: Leverages MacroGenics’ actual financial data for dependable valuation results.
- Streamlined Scenario Testing: Easily evaluate various assumptions and analyze the resulting impacts.
- Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file for MacroGenics, Inc. (MGNX).
- Step 2: Review MacroGenics’ pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for MacroGenics, Inc. (MGNX)?
- Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses in a single solution.
- Customizable Inputs: Modify the yellow-highlighted cells to explore different scenarios.
- Detailed Insights: Automatically computes MacroGenics' intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points.
- Professional Quality: Perfect for financial analysts, investors, and business consultants.
Who Should Use This Product?
- Investors: Accurately evaluate MacroGenics, Inc.’s (MGNX) fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to MacroGenics, Inc. (MGNX).
- Consultants: Efficiently customize the template for valuation reports tailored to MacroGenics, Inc. (MGNX) clients.
- Entrepreneurs: Acquire insights into the financial modeling practices of leading biotech firms like MacroGenics, Inc. (MGNX).
- Educators: Employ it as a teaching resource to illustrate valuation methodologies relevant to MacroGenics, Inc. (MGNX).
What the Template Contains
- Pre-Filled DCF Model: MacroGenics, Inc.’s (MGNX) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate MacroGenics, Inc.’s (MGNX) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.